Faruqi & Faruqi, LLP Securities Litigation Partner\u00a0<\/strong>James (Josh) Wilson<\/strong><\/a> Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options<\/strong><\/p>\n If you purchased or acquired securities in <\/strong>Skye<\/strong><\/a> between November 4, 2024 and October 3, 2025 <\/strong>and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly <\/strong>at 877-247-4292 <\/strong>or 212-983-9330 (Ext. 1310)<\/strong>.<\/p>\n [You may also click here for additional information]<\/strong><\/a><\/p>\n NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP<\/a>, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. (\u201cSkye\u201d or the \u201cCompany\u201d) (NYSE: SKYE) and reminds investors of the January 16, 2026 deadline<\/strong> to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.<\/p>\n Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com<\/a>.<\/p>\n As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and\/or misleading statements and\/or failing to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab\u2019s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants\u2019 public statements were materially false and misleading at all relevant times.<\/p>\n On October 6, 2025, Skye issued a press release “announcing the topline data from its 26-week Phase 2a CBeyond\u2122 proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”<\/p>\n On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.<\/p>\n The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.<\/p>\n Faruqi & Faruqi, LLP also encourages anyone with information regarding Skye\u2019s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.<\/p>\n To learn more about the Skye Bioscience<\/strong> class action, go to www.faruqilaw.com\/SKYE<\/strong><\/a> or call<\/strong> Faruqi & Faruqi partner Josh Wilson directly <\/strong>at 877-247-4292 <\/strong>or 212-983-9330 (Ext. 1310)<\/strong>.<\/p>\n Follow us for updates on LinkedIn<\/a>, on X<\/a>, or on Facebook<\/a>.<\/p>\n Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.<\/p>\n![\"James](\"https:\/\/ml.globenewswire.com\/Resource\/Download\/1c84fcf7-a77f-4c3f-a1dd-153f7bf3d4ac\/image1.png\")
<\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/YmY1YmM2YzktMzcxYi00YTJlLWJlZDAtYWMzYmFjNjI2NzgzLTEwMjkyMDktMjAyNS0xMi0yNi1lbg==\/tiny\/Faruqi-Faruqi-LLP.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"